Morgan Stanley downgraded Demant to Underweight from Equal Weight with a DKK 255 price target. The rating change is part of the firm’s 2024 outlook for European medical technology and services. The analyst expects earnings delivery to play a more prominent role in relative winners and losers in 2024 versus a multiple dominated 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on WILYY: